Guillain-Barre Syndrome Market is Projected to Witness Significant Growth by 2036 Owing to Advancements in Targeted Immunotherapies and Emerging Disease-Modifying Treatments | DelveInsight

The Guillain-Barre Syndrome Market is anticipated to witness substantial growth during the forecast period, driven by the growing awareness and early diagnosis, advancements in supportive care, and the development of targeted immunotherapies. The emergence of promising therapies such as Tanruprubart, Imlifidase, and other novel pipeline candidates is expected to significantly transform the Guillain-Barre Syndrome Treatment Market over the coming years.
DelveInsight, a leading market research and business consulting firm specializing in life sciences, has published its latest report, "Guillain-Barre Syndrome (GBS) Market Insights, Epidemiology, and Market Forecast - 2036." The report provides a comprehensive assessment of the Guillain-Barre Syndrome Market Size, GBS Epidemiology, current treatment landscape, Guillain-Barre Syndrome Pipeline, emerging therapies, competitive intelligence, and market forecasts across the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan (7MM).

Keen to know how the Guillain-Barre Syndrome Market will evolve by 2036? Request our sample page at https://www.delveinsight.com/sample-request/guillain-barre-syndrome-gbs-market [https://www.delveinsight.com/sample-request/guillain-barre-syndrome-gbs-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=kspr]

Key Takeaways from the Guillain-Barre Syndrome Market

*
The Guillain-Barre Syndrome Market Size across the seven major markets (7MM) is expected to witness significant growth during the forecast period (2022-2036), driven by increasing disease awareness, improved diagnosis, expanding treatment options, and the anticipated launch of innovative targeted therapies.

*
According to DelveInsight's analysis, the Guillain-Barre Syndrome Market is projected to grow from approximately USD 237.6 million in 2022 to nearly USD 2,729.4 million by 2036, reflecting the anticipated commercialization of emerging therapies and increasing adoption of novel treatment approaches.

*
The United States accounted for the largest Guillain-Barre Syndrome Market among the seven major markets and is expected to maintain its leadership throughout the forecast period owing to higher healthcare expenditure, increasing diagnosis rates, and rapid adoption of innovative therapies.

*
According to the Centers for Disease Control and Prevention (CDC, 2024), approximately 3,000-6,000 people develop Guillain-Barre Syndrome annually in the United States.

*
According to the National Organization for Rare Disorders (NORD, 2024), Guillain-Barre Syndrome has an estimated annual incidence of approximately 1-2 cases per 100,000 individuals, with nearly half of patients reporting a preceding gastrointestinal or respiratory infection before symptom onset.

*
Secondary research indicates that the incidence of Guillain-Barre Syndrome is approximately 1.66 cases per 100,000 population in Spain, around 2 cases per 100,000 population annually in the United Kingdom, and 2.42 cases per 100,000 person-years in France.

*
According to the World Health Organization (WHO), Guillain-Barre Syndrome can affect individuals of all ages but occurs more frequently in adults and males.

*
The current treatment landscape primarily consists of intravenous immunoglobulin (IVIG) and plasma exchange (plasmapheresis), while emerging therapies such as Tanruprubart (ANX005) and Imlifidase are expected to reshape the future Guillain-Barre Syndrome Treatment Market by targeting disease-specific immune mechanisms.

Key Factors Driving the Guillain-Barre Syndrome Market

Increasing Incidence and Improved Disease Recognition

Growing awareness among healthcare professionals, improved diagnostic capabilities, and better recognition of neurological disorders are contributing to earlier diagnosis and timely treatment of Guillain-Barre Syndrome. These factors are expanding the diagnosed patient pool and supporting long-term growth of the Guillain-Barre Syndrome Market.

Advancements in Targeted Immunotherapies

The development of innovative therapies targeting complement activation, pathogenic antibodies, and immune-mediated nerve injury is transforming the Guillain-Barre Syndrome Pipeline. Novel therapies such as Tanruprubart (ANX005) and Imlifidase have the potential to improve functional recovery, reduce disease severity, and address significant unmet medical needs beyond conventional immune modulation.

Growing Demand for Disease-Modifying Therapies

Although IVIG and plasma exchange remain the current standards of care, they do not specifically target the underlying disease mechanisms. The anticipated introduction of targeted biologics and rapid-acting immunotherapies is expected to expand therapeutic options and accelerate growth within the Guillain-Barre Syndrome Therapeutics Market throughout the forecast period.

Guillain-Barre Syndrome Competitive Landscape

*
The Guillain-Barre Syndrome (GBS) Market is witnessing a notable shift as pharmaceutical and biotechnology companies increasingly focus on developing targeted disease-modifying therapies that address the underlying immune mechanisms responsible for nerve damage. Although intravenous immunoglobulin (IVIG) and plasma exchange (plasmapheresis) remain the cornerstone of GBS management, there are currently no approved targeted therapies specifically designed to modify disease progression, highlighting a significant opportunity for innovation in the Guillain-Barre Syndrome Treatment Market.

*
The GBS Pipeline is advancing with several promising investigational therapies, led by Tanruprubart (ANX005) from Annexon and Imlifidase from Hansa Biopharma. These therapies are designed to rapidly suppress immune-mediated nerve injury through novel mechanisms of action and have the potential to improve neurological recovery, reduce disability, and shorten the duration of hospitalization in patients with acute Guillain-Barre Syndrome.

*
Tanruprubart (ANX005) is a first-in-class intravenous C1q complement inhibitor developed to rapidly reduce neuroinflammation and prevent immune-mediated nerve damage by blocking activation of the classical complement pathway. The therapy has received Fast Track Designation (FTD) and Orphan Drug Designation (ODD) from the US FDA, along with orphan designation from the European Medicines Agency (EMA), and is currently being evaluated in the Phase III FORWARD clinical trial.

*
Imlifidase, developed by Hansa Biopharma, is a novel IgG-cleaving enzyme derived from Streptococcus pyogenes that rapidly degrades pathogenic IgG antibodies, thereby suppressing immune-mediated nerve injury. The therapy has completed Phase II clinical evaluation, demonstrating encouraging clinical outcomes in patients with severe Guillain-Barre Syndrome.

Discover more about therapies expected to transform the Guillain-Barre Syndrome Treatment Market and gain significant market share @ Guillain-Barre Syndrome Treatment Landscape [https://www.delveinsight.com/sample-request/guillain-barre-syndrome-gbs-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=kspr]

Recent Developments in the Guillain-Barre Syndrome Market

*
In January 2026, Annexon announced the submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) seeking approval of Tanruprubart (ANX005) for the treatment of Guillain-Barre Syndrome.

*
In May 2025, Annexon presented new clinical data from Tanruprubart (ANX005) at the Peripheral Nerve Society (PNS) Annual Meeting, demonstrating improved clinical outcomes in patients with Guillain-Barre Syndrome.

*
Initial data from the Phase III FORWARD study evaluating Tanruprubart (ANX005) across the United States and Europe are anticipated in 2026, with submission of a Biologics License Application (BLA) to the US FDA expected during the same year.

*
In May 2025, Hansa Biopharma presented positive Phase II clinical data for Imlifidase at the Peripheral Nerve Society Annual Meeting, highlighting its potential to rapidly improve functional recovery in patients with Guillain-Barre Syndrome.

*
In December 2024, Hansa Biopharma announced positive results from its 15-HMedIdeS-09 Phase II study, demonstrating that patients receiving Imlifidase plus IVIG experienced faster muscle strength recovery and achieved independent walking in a median of 16 days, compared with historical outcomes.

What is Guillain-Barre Syndrome?

Guillain-Barre Syndrome (GBS) is a rare, acute autoimmune neurological disorder in which the body's immune system mistakenly attacks the peripheral nervous system. The disease typically develops rapidly over hours to weeks and can progress from mild muscle weakness to severe paralysis, respiratory failure, and life-threatening autonomic dysfunction if left untreated.

GBS is commonly preceded by bacterial or viral infections, particularly Campylobacter jejuni, influenza, cytomegalovirus, Epstein-Barr virus, or Zika virus infections. Diagnosis is based on clinical findings, supported by nerve conduction studies demonstrating slowed nerve conduction and cerebrospinal fluid (CSF) analysis showing elevated protein levels with normal white blood cell counts.

Although there is currently no cure for Guillain-Barre Syndrome, early initiation of IVIG or plasma exchange can significantly reduce disease severity and accelerate recovery. Supportive care, respiratory monitoring, rehabilitation, physiotherapy, and multidisciplinary management remain essential components of patient care, particularly for individuals with severe disease.

Guillain-Barre Syndrome Epidemiology Segmentation

The Guillain-Barre Syndrome Epidemiology section provides historical and forecasted patient population insights across the seven major markets during the study period 2022-2036. The report analyzes:

*
Total Incident Cases of Guillain-Barre Syndrome

*
Gender-specific Cases of Guillain-Barre Syndrome

*
Age-specific Cases of Guillain-Barre Syndrome

*
Total Treated Cases of Guillain-Barre Syndrome

Scope of the Guillain-Barre Syndrome Market Report

*
Therapeutic Assessment: Current and Emerging Guillain-Barre Syndrome Therapies

*
Guillain-Barre Syndrome Market Dynamics: Market Forecast, Key Assumptions, Emerging Drugs, and Future Market Outlook

*
Key Companies: Annexon, Hansa Biopharma, and others

*
Key Therapies: Tanruprubart (ANX005), Imlifidase, IVIG, Plasma Exchange, and others

*
Competitive Intelligence: SWOT Analysis, Market Access, Pricing Trends, Analogue Assessment, and Reimbursement Analysis

*
Unmet Needs, KOL Perspectives, Analyst Views, and Future Market Opportunities

Interested in learning about the future treatment landscape? Explore the latest Guillain-Barre Syndrome Pipeline, Clinical Trials, and Emerging Drugs @ Guillain-Barre Syndrome Clinical Trials and Therapeutic Assessment [https://www.delveinsight.com/sample-request/guillain-barre-syndrome-gbs-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=kspr]

Table of Contents

*
Guillain-Barre Syndrome Market Report Introduction

*
Executive Summary of Guillain-Barre Syndrome

*
SWOT Analysis of Guillain-Barre Syndrome

*
Guillain-Barre Syndrome Patient Share (%) Overview at a Glance

*
Guillain-Barre Syndrome Market Overview at a Glance

*
Guillain-Barre Syndrome Disease Background and Overview

*
Guillain-Barre Syndrome Epidemiology and Patient Population

*
Country-specific Patient Population of Guillain-Barre Syndrome

*
Current Treatment Landscape and Medical Practices

*
Guillain-Barre Syndrome Unmet Needs

*
Emerging Therapies for Guillain-Barre Syndrome

*
Guillain-Barre Syndrome Market Outlook

*
Country-wise Guillain-Barre Syndrome Market Analysis (2022-2036)

*
Market Access and Reimbursement

*
Guillain-Barre Syndrome Market Drivers

*
Guillain-Barre Syndrome Market Barriers

*
Appendix

*
Report Methodology

*
DelveInsight Capabilities

*
Disclaimer

*
About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kirti Sharma
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=guillainbarr-syndrome-market-is-projected-to-witness-significant-growth-by-2036-owing-to-advancements-in-targeted-immunotherapies-and-emerging-diseasemodifying-treatments-delveinsight]
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.